Bio-XL
Developing Biopharma solutions
to undertreated medical needs
Member of the @ARC innovation at Sheba
CancerPredict
Screening test enabling cancer prediction years before its development.
Prediction allows preventive treatment, improve treatments outcomes, increase survival rate and improve quality of life
Screening test (addition to the current common checkup), using digital pathology method and
big data system assysted by AI.
Project funded by grant (pre-SEED)
CeaseCancer
Universal Anti-cancer drug
enabling efficient therapy w/o compromising safety
Personalized medicine leads to expensive cancer therapy, not accessible to most of people.
Chemotherapy, despite reluctance remains main drug treatment.
CeaseCancer, as a drug treatment with unique MoA, high safety profile and wide array of cancer types and stages, will enable replacement of chemo, or, in combination- reduce doses, to minimize adverse side effects
The first indications: TNBC and PDAC
Pre-SEED/SEED fund round now open
CancerPredict and CeaseCancer technologies rely on IP of Sheba Medical Center's (Israel) and Cedar Sinai medical center (US).
Bio-XL has the worldwide exclusive license for the commercialization of the technologies
Contact Us
Nahal Snir 15, Yavne, Israel
meir.biom@gmail.com | Tel: +972-549-536-396